b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">30582435</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>02</Month>\n            <Day>06</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>02</Month>\n            <Day>15</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1744-7607</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>15</Volume>\n                    <Issue>2</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>Feb</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Expert opinion on drug metabolism &amp; toxicology</Title>\n                <ISOAbbreviation>Expert Opin Drug Metab Toxicol</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Overcoming barriers to optimal drug dosing during ECMO in critically ill adult patients.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>103-112</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1080/17425255.2019.1563596</ELocationID>\n            <Abstract>\n                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">One major challenge to achieving optimal patient outcome in extracorporeal membrane oxygenation (ECMO) is the development of effective dosing strategies in this critically ill patient population. Suboptimal drug dosing impacts on patient outcome as patients on ECMO often require reversal of the underlying pathology with effective pharmacotherapy in order to be liberated of the life-support device. Areas covered: This article provides a concise review of the effective use of antibiotics, analgesics, and sedative by characterizing the specific changes in PK secondary to the introduction of the ECMO support. We also discuss the barriers to achieving optimal pharmacotherapy in patients on ECMO and also the current and potential research that can be undertaken to address these clinical challenges. Expert opinion: Decreased bioavailability due to sequestration of drugs in the ECMO circuit and ECMO induced PK alterations are both significant barriers to optimal drug dosing. Evidence-based drug choices may minimize sequestration in the circuit and would enable safety and efficacy to be maintained. More work to characterize ECMO related pharmacodynamic alterations such as effects of ECMO on hepatic cytochrome system are still needed. Novel techniques to increase target site concentrations should also be explored.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Cheng</LastName>\n                    <ForeName>Vesa</ForeName>\n                    <Initials>V</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Faculty of Medicine , University of Queensland Centre for Clinical Research (UQCCR), The University of Queensland , Brisbane , Australia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Abdul-Aziz</LastName>\n                    <ForeName>Mohd H</ForeName>\n                    <Initials>MH</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Faculty of Medicine , University of Queensland Centre for Clinical Research (UQCCR), The University of Queensland , Brisbane , Australia.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>b School of Pharmacy , International Islamic University Malaysia , Kuantan , Malaysia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Roberts</LastName>\n                    <ForeName>Jason A</ForeName>\n                    <Initials>JA</Initials>\n                    <Identifier Source="ORCID">http://orcid.org/0000-0001-6218-435X</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>a Faculty of Medicine , University of Queensland Centre for Clinical Research (UQCCR), The University of Queensland , Brisbane , Australia.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>c Department of Intensive Care Medicine , Royal Brisbane and Women\'s Hospital , Brisbane , Australia.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>d Department of Pharmacy , Royal Brisbane and Women\'s Hospital , Brisbane , Australia.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>e Centre for Translational Anti-infective Pharmacodynamics, School of Pharmacy , The University of Queensland , Brisbane , Australia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Shekar</LastName>\n                    <ForeName>Kiran</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>f Adult Intensive Care Services , The Prince Charles Hospital , Chermside , Australia.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>g Critical Care Research Group , Centre of Research Excellence for Advanced Cardio-respiratory Therapies Improving OrgaN Support (ACTIONS) and the University of Queensland , Brisbane , Australia.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>h Faculty of Health Sciences and Medicine , Bond University , Gold Coast , Australia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016454">Review</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>01</Month>\n                <Day>03</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Expert Opin Drug Metab Toxicol</MedlineTA>\n            <NlmUniqueID>101228422</NlmUniqueID>\n            <ISSNLinking>1742-5255</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000700">Analgesics</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D006993">Hypnotics and Sedatives</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000700" MajorTopicYN="N">Analgesics</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName>\n                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006993" MajorTopicYN="N">Hypnotics and Sedatives</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Critical illness</Keyword>\n            <Keyword MajorTopicYN="N">ECMO</Keyword>\n            <Keyword MajorTopicYN="N">analgesics</Keyword>\n            <Keyword MajorTopicYN="N">antibiotics</Keyword>\n            <Keyword MajorTopicYN="N">pharmacodynamics</Keyword>\n            <Keyword MajorTopicYN="N">pharmacokinetics</Keyword>\n            <Keyword MajorTopicYN="N">sedatives</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>12</Month>\n                <Day>26</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>2</Month>\n                <Day>7</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>12</Month>\n                <Day>25</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30582435</ArticleId>\n            <ArticleId IdType="doi">10.1080/17425255.2019.1563596</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'